Compare e l f Beauty Inc (ELF) vs Sana Biotechnology Inc (SANA) Price & Performance

ELF Beauty trades at $92.62, down 2.75% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $1.75 surpassing the $0.714 expectation, and revenue growth remains robust at 36% in Q1 2027. Analyst sentiment is mixed with a 46.43% buy rating, while technical indicators show overbought RSI levels but bullish moving averages. Recent news highlights expansion into hair care and a $50 million tariff windfall boosting profitability.

The outlook for ELF is positive due to sustained revenue growth and strategic expansions, but risks include high valuation multiples and reliance on acquisitions for growth. The stock's current price is near the consensus target of $91.14, suggesting limited upside unless earnings continue to exceed expectations. Investors should weigh the strong operational performance against elevated P/E and EV/EBITDA ratios.

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.